Company Vision
practise medicine in order to help the people,
ethical pursuit of goodness;
brave the wind and the waves,
outdo yourself,
honesty and trustworthiness,
win-win cooperation;
hard work,
confident and brave.
MHDC focus on research and development of novel pharmaceutical dosage forms, and manufacture of high-level drug dosage forms and medical devices.
Main investors are oversea PhD group, Entrepreneurial team have rich knowledge and experience in global advanced formulation /device/cGMP technology. Amongst them, several members are elected as Zhejiang Provincial Overseas Experts and Shaoxing 330 High-level Talents.
Since start up, MHDC have raised fund from listed companies, banks, governmental and industrial fund. At the beginning of 2021, a B-round fund-raising of 100 million RMB was completed.
When the company was founded, its main entrepreneurial project was the research and development of solid extended-release drugs. At present, the company‘s core business has developed into the R & D and industrialization of solid extended-release drugs, microsphere sustained-release injectables, class-3 medical devices and NDA new drugs. Products include minocycline hydrochloride Extended-release tablets, exenatide / liraglutide sustained-release microspheres, proteasome inhibitors, anti-tumor innovative drugs, hemostatic dressings and others, totally more than 20 products.
Microsphere sustained-release preparation R&D and industrialization platform
The platform has accumulated the most effective product with the lowest cost in just 5 years. At present, it has accumulated 5 microsphere product projects and the production of commercial-grade batches under GMP conditions has been scaled up. Now the preparation specifications have reached (120,000 pieces/batch) compared with only 3,000 pieces/batch for some production-level batches. The specifications are much higher than batches. The current commercial batch amplification equipment is independently designed by Meihua Dingchang, and the patent application has been completed. A number of microsphere research and development technologies have applied for patents.
Solid sustained-release preparation R&D and industrialization platform
We have established a research and development platform for solid sustained-release preparations with multiple varieties (such as minocycline hydrochloride sustained-release tablets, aripiprazole sustained-release tablets, etc.)The platform could solve the problem of solid sustained-release preparation R&D with low level. It could also achieve the goal of quickly entering the international high-end market. In just a few years, we have developed and matured the formulation process and quality standards of many generic drugs.
High-end medical device R&D and industrialization platform
Meihua Dingchang started the research and development of high-end medical devices in 2015, and successfully developed a dissolvable nasal dressing project and a cross-linked sodium hyaluronate gel project in few years.The dissolvable nasal dressing project has completed the research and development, and is entering the GMP pilot scale-up stage and the clinical application stage. The dissolvable hemostasis and anti-adhesion nasal dressing is the first variety. High-end medical products are developed and researched, including nose and ear , dental and other postoperative blood adhesion prevention. The new generation of dissolvable hemostatic anti-adhesion nasal dressing has obtained the approval number of the US FDA medical device. The cross-linked sodium hyaluronate gel project has completed the pilot stage and entered the pilot scale-up stage.
